An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Aug 2016
At a glance
- Drugs Golvatinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 18 Aug 2016 The trial was completed in Belgium.
- 06 May 2016 The trial is completed in Spain (end date: 2015-04-30) and Italy (end date: 2015-06-30).
- 16 Sep 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History